Accessibility Menu
Lumos Diagnostics logo

Lumos Diagnostics(ASX) LDX

Market CapA$108.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-90%
5 Year-91%
1 Year+22%
1 Month+34%
A$0.11
-4.35%
-0.01Today
Lumos Diagnostics last closing stock price
MetricPriceDate
Last closeAUD 0.122026-08-13
Lumos Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8%AUD 0.132026-08-06
1 month+33.72%AUD 0.092026-07-14
3 month-8%AUD 0.132026-05-15
Year to date-59.65%AUD 0.292025-12-31
1 year+22.34%AUD 0.092025-08-13
3 year+53.33%AUD 0.082023-08-14
5 year-90.69%AUD 1.242021-08-13
Since inception-89.85%AUD 1.132021-07-05

Lumos Diagnostics Financials at a Glance

Market Cap

A$108.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$27.00M

Net Income (TTM)

-$14.33M

EPS (TTM)

-A$0.02

P/E Ratio

-6.08

Dividend

A$0.00

Beta (Volatility)

-0.03 (Low)

Price

A$0.11

Volume

743,107

Open

A$0.12

Previous Close

A$0.12

Daily Range

A$0.11 - A$0.12

52-Week Range

A$0.08 - A$0.33

Estimated Earnings Date

Sep 1, 2026

LDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lumos Diagnostics

Lumos Diagnostics Holdings Limited is a healthcare company focused on developing, manufacturing, and commercializing point-of-care diagnostic products for infectious diseases. Based in Carlsbad, California, the company offers innovative solutions such as FebriDx and ViraDx, which are designed to enhance diagnostic accuracy and speed.

Products and Services
  • FebriDx: A test for differentiating viral and bacterial respiratory infections
  • ViraDx: A three-in-one test for influenza A, influenza B, and COVID-19
  • Assay development and manufacturing services for point-of-care tests
Growth Outlook
  • Increasing demand for rapid diagnostic tests in the U.S. healthcare market
  • Expansion of product offerings to address emerging infectious diseases
  • Strategic partnerships to enhance distribution and market reach
Financial Highlights
  • Recent quarterly revenue of $6.23 million, showing growth potential
  • Trailing twelve months (TTM) revenue of $25.5 million, indicating strong market presence
  • Operating expenses reduced by 15% compared to the previous quarter
Lumos Diagnostics Holdings Limited is positioned in a growing sector with a focus on innovative diagnostic solutions. The company's products are designed to meet the increasing demand for rapid and accurate testing, particularly in the context of infectious diseases. Recent financial performance indicates a positive trajectory, with significant revenue growth and a commitment to reducing operating expenses. The strategic focus on partnerships and expanding product lines further enhances the company's potential for future growth. Investors may find Lumos Diagnostics Holdings Limited an intriguing opportunity within the healthcare sector.
AI Generated • Jul 22, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Douglas Ward

Website

www.lumosdiagnostics.com

Headquarters

Melbourne, VIC 3000, AU

LDX Financials

Key Financial Metrics (TTM)

Gross Margin

2.96%

Operating Margin

-81.50%

Net Income Margin

-75.84%

Return on Equity

-164.12%

Return on Capital

-59.67%

Return on Assets

-44.27%

Earnings Yield

-16.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$108.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

944.82M

Volume

743.11K

Avg. Volume

3.24M

Financials (TTM)

Gross Profit

$9.73M

Operating Income

-$12.88M

EBITDA

-$12.79M

Operating Cash Flow

-$2.77M

Capital Expenditure

-$285.41K

Free Cash Flow

-$3.05M

Cash & ST Invst.

$3.00M

Total Debt

$11.85M

Lumos Diagnostics Performance Analysis

Lumos Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 16,035,059N/A
20232023-06-30USD 15,660,665-2.3%
20242024-06-30USD 16,984,1698.5%
20252025-06-30USD 19,146,70612.7%
Lumos Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30202.4%
Q22024-12-30-24.6%
Q42025-06-30-3.4%
Q22025-12-312.3%
Lumos Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.39N/A
20232023-06-30USD -0.05-86.3%
20242024-06-30USD -0.03-50.1%
20252025-06-30USD -0.02-38.7%
Lumos Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3068.1%
Q22024-12-30N/A
Q42025-06-30-26.1%
Q22025-12-31-10.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$6.23M

+125.3%

Gross Profit

-$3.08M

-314.3%

Gross Margin

-49.35%

N/A

Market Cap

A$108.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$3.75M

N/A

Employees

29

N/A

Net Income

-$4.97M

+22.5%

EBITDA

-$5.33M

-21.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.00M

+117.3%

Total Debt

$11.85M

+39.0%

Accounts Receivable

$1.97M

+96.9%

Inventory

$1.06M

-20.4%

Long Term Debt

$10.76M

+41.1%

Short Term Debt

$1.10M

+21.1%

Return on Assets

-44.27%

N/A

Return on Invested Capital

-94.66%

N/A

Free Cash Flow

$588.62K

+112.1%

Operating Cash Flow

$778.03K

+116.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PAR.AXParadigm Biopharmaceuticals Limited
A$0.18+0.00%
AHC.AXAustco Healthcare Limited
A$0.23+0.00%
SOM.AXSomnoMed Limited
A$0.35-5.41%
ONE.AXOneview Healthcare PLC
A$0.17+3.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About LDX

What is the current price of Lumos Diagnostics?

Lumos Diagnostics is trading at A$0.11 per share.

What is the 52-week range for Lumos Diagnostics?

Over the past 52 weeks, Lumos Diagnostics has traded between A$0.08 and A$0.33.

How much debt does Lumos Diagnostics have?

As of the most recent reporting period, Lumos Diagnostics reported total debt of $10.66M.

How much cash does Lumos Diagnostics have on hand?

Lumos Diagnostics reported $2.98M in cash and cash equivalents in its most recent financial results.

What is Lumos Diagnostics’s dividend yield?

Lumos Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services